Program overview
Context
Indication: Head and Neck Cancer
Mechanism: Unknown
Modality: Unknown
Sponsor: University of Chicago
Registry Stop Signal
Everolimus (RAD 001)
Everolimus (RAD 001) is flagged as registry stop signal because public records show a registry stop signal. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.
Scores
Risk-signal summary
Registry: 5/5
Timeline: 1/5
Recruitment burden: 0/5
Results availability: 0/5
Program risk: 3/5
Evidence
Public links
https://clinicaltrials.gov/study/NCT01111058
Linked trials
Trial-level signal details
| Trial | Status | Timeline | Results | Burden |
|---|---|---|---|---|
| NCT01111058 | Registry Stop Signal (TERMINATED) | stale_update_signal | Low Signal | None |